Targeting pan-essential genes in cancer: challenges and opportunities

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

(2020) Jenny Y. Xue et al.   NATURE

Titrating gene expression using libraries of systematically attenuated CRISPR guide RNAs

(2020) Marco Jost et al.   NATURE BIOTECHNOLOGY

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

(2020) Mónica Álvarez-Fernández et al.   CANCER CELL

Functional Genomics for Cancer Drug Target Discovery

(2020) Benjamin Haley et al.   CANCER CELL

Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).

(2020) Joyce O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9–Cas12a platform

(2020) Thomas Gonatopoulos-Pournatzis et al.   NATURE BIOTECHNOLOGY

Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities

(2020) Caitlin A. Nichols et al.   Nature Communications

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

(2020) Michael A. Gillette et al.   CELL

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Alterations in the RAF–MEK Pathway

(2019) Rona Yaeger et al.   Cancer Discovery

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

(2019) Owen A. O’Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

(2019) Fiona M. Behan et al.   NATURE

Next-generation characterization of the Cancer Cell Line Encyclopedia

(2019) Mahmoud Ghandi et al.   NATURE

The landscape of cancer cell line metabolism

(2019) Haoxin Li et al.   NATURE MEDICINE

Essential Gene Profiles for Human Pluripotent Stem Cells Identify Uncharacterized Genes and Substrate Dependencies

(2019) Barbara Mair et al.   Cell Reports

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor

(2019) Kenichi Iwai et al.   Science Advances

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

(2019) Seock-Ah Im et al.   NEW ENGLAND JOURNAL OF MEDICINE

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

(2019) Jordi Bertran-Alamillo et al.   Nature Communications

Antibody-Drug Conjugates: A Comprehensive Review

(2019) Puregmaa Khongorzul et al.   MOLECULAR CANCER RESEARCH

The human body at cellular resolution: the NIH Human Biomolecular Atlas Program

(2019)   NATURE

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Synthetic lethality as an engine for cancer drug target discovery

(2019) Alan Huang et al.   NATURE REVIEWS DRUG DISCOVERY

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers

(2019) Fengju Chen et al.   Nature Communications

Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets

(2019) Joshua M. Dempster et al.   Nature Communications

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

Defining essential genes for human pluripotent stem cells by CRISPR–Cas9 screening in haploid cells

(2018) Atilgan Yilmaz et al.   NATURE CELL BIOLOGY

The dTAG system for immediate and target-specific protein degradation

(2018) Behnam Nabet et al.   Nature Chemical Biology

Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer

(2018) Srinivas R. Viswanathan et al.   NATURE GENETICS

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

(2018) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?

(2018) Kulmira Nurgali et al.   Frontiers in Pharmacology

Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201

(2018) Sébastien Jeay et al.   CANCER RESEARCH

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

(2018) Krijn K. Dijkstra et al.   CELL

First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.

(2018) Toshio Shimizu et al.   JOURNAL OF CLINICAL ONCOLOGY

Plk1 overexpression induces chromosomal instability and suppresses tumor development

(2018) Guillermo de Cárcer et al.   Nature Communications

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

(2018) Khyati N. Shah et al.   NATURE MEDICINE

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions

(2017) Kyuho Han et al.   NATURE BIOTECHNOLOGY

Emerging and evolving concepts in gene essentiality

(2017) Giulia Rancati et al.   NATURE REVIEWS GENETICS

Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma

(2017) Rintaro HASHIZUME   NEUROLOGIA MEDICO-CHIRURGICA

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Human Cell Atlas

(2017) Aviv Regev et al.   eLife

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

(2016) Elizabeth C. Townsend et al.   CANCER CELL

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

(2016) Klaus Mross et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Landscape of Pharmacogenomic Interactions in Cancer

(2016) Francesco Iorio et al.   CELL

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

(2016) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

(2016) Guillermo Garcia-Manero et al.   LANCET ONCOLOGY

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines

(2016) Channing Yu et al.   NATURE BIOTECHNOLOGY

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

(2016) Susan Ashton et al.   Science Translational Medicine

Rapid Protein Depletion in Human Cells by Auxin-Inducible Degron Tagging with Short Homology Donors

(2016) Toyoaki Natsume et al.   Cell Reports

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

(2016) Jesús F San-Miguel et al.   Lancet Haematology

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

(2015) B. H. O'Neil et al.   ANNALS OF ONCOLOGY

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities

(2015) Traver Hart et al.   CELL

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer

(2015) Peter M. Ellis et al.   Clinical Lung Cancer

The auxin-inducible degradation (AID) system enables versatile conditional protein depletion in C. elegans

(2015) L. Zhang et al.   DEVELOPMENT

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

(2015) Lee M Krug et al.   LANCET ONCOLOGY

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

canSAR: an updated cancer research and drug discovery knowledgebase

(2015) Joseph E. Tym et al.   NUCLEIC ACIDS RESEARCH

Gene essentiality and synthetic lethality in haploid human cells

(2015) V. A. Blomen et al.   SCIENCE

The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans

(2015) et al.   SCIENCE

Identification and characterization of essential genes in the human genome

(2015) T. Wang et al.   SCIENCE

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset

(2015) B. Seashore-Ludlow et al.   Cancer Discovery

Regulation and roles of Cdc7 kinase under replication stress

(2014) Masayuki Yamada et al.   CELL CYCLE

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

(2013) Walter M. Stadler et al.   CANCER

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

(2013) Hagop M. Kantarjian et al.   CANCER

Aurora kinases in head and neck cancer

(2013) Ranee Mehra et al.   LANCET ONCOLOGY

Discovery of XL413, a potent and selective CDC7 inhibitor

(2012) Elena S. Koltun et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

(2011) Monika Raab et al.   Nature Communications

Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy

(2010) A. Montagnoli et al.   CLINICAL CANCER RESEARCH

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)

(2009) R.C.F. Leonard et al.   BREAST

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma

(2009) A. A. Kulkarni et al.   CLINICAL CANCER RESEARCH

Polo-Like Kinase 1 Is Essential for Early Embryonic Development and Tumor Suppression

(2008) L.-Y. Lu et al.   MOLECULAR AND CELLULAR BIOLOGY

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity

(2008) Alessia Montagnoli et al.   Nature Chemical Biology

Chemical control of protein stability and function in living mice

(2008) Laura A Banaszynski et al.   NATURE MEDICINE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA